Targeted HER2 Treatment in Advanced Gastric Cancer

Publisher： Karger

E-ISSN： 1423-0232|78|1|26-33

ISSN： 0030-2414

Source： Oncology, Vol.78, Iss.1, 2010-02, pp. : 26-33

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer

By  

Oncology, Vol. 88, Iss. 2, 2014-10 ,pp. : 76-85

Karger

Access to resources Recommend Favorite

Targeted Therapy in HER2-Positive Breast Cancer

By  

Oncology Research and Treatment, Vol. 39, Iss. 5, 2016-04 ,pp. : 295-302

Karger

Access to resources Recommend Favorite

Targeted Therapy of HER2-Negative Breast Cancer

By  

Oncology Research and Treatment, Vol. 39, Iss. 3, 2016-02 ,pp. : 118-121

Karger

Access to resources Recommend Favorite

Treatment of Advanced Gastric Cancer: Where We Are in 2003

By  

Oncology Research and Treatment, Vol. 26, Iss. 3, 2003-07 ,pp. : 214-215

Karger

Access to resources Recommend Favorite

Successful Treatment of a Patient with HER2-Positive Metastatic Gastric Cancer with Third-Line Combination Therapy with Irinotecan, 5-Fluorouracil, Leucovorin and Trastuzumab (FOLFIRI-T)

By  

Oncology Research and Treatment, Vol. 34, Iss. 10, 2011-09 ,pp. : 548-551

Karger

Access to resources Recommend Favorite